Class of warrant or right exercisable number.

No definition available.

Name:	srne_ClassOfWarrantOrRightExercisableNumber
Namespace Prefix:	srne_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Class of warrant or right, period in which warrants can be exercised from grant date

+ References

No definition available.

+ Details

Name:	srne_ClassOfWarrantOrRightPeriodInWhichWarrantsCanBeExercisedFromGrantDate
Namespace Prefix:	srne_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Employee service share based compensation nonvested awards compensation cost not yet recognized stock options and warrants.

+ References

No definition available.

+ Details

Name:	srne_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedStockOptionsAndWarrants
Namespace Prefix:	srne_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Share based compensation employee option grants vesting rate.

+ References

No definition available.

+ Details

Name:	srne_ShareBasedCompensationEmployeeOptionGrantsVestingRate
Namespace Prefix:	srne_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
-Section F

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

+ Details

Name:	us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

+ Details

Name:	us-gaap_CommonStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name:	us-gaap_CommonStockVotingRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name:	us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

For each plan, identification of the award pricing model or other valuation method used in calculating the weighted average fair values disclosed. The model is also used to calculate the compensation expense that is shown within the balance sheet, income statement, and cash flow. Examples of valuation techniques are lattice models (binomial model), closed-form models (Black-Scholes-Merton formula), and a Monte Carlo simulation technique. Fair value is the amount at which an asset or liability could be bought or incurred or sold or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale. May include disclosures about the assumptions underlying application of the method selected.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
-Section D
-Subsection 2

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Weighted average grant-date fair value of options vested.

+ References

No definition available.

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=srne_TwoThousandNineNonEmployeeDirectorGrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=srne_NonEmployeeDirectorsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=srne_TwoThousandNineStockIncentivePlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=srne_EmployeeAndDirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=srne_NonEmployeeConsultantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=srne_SubsidiaryEquityGrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_TNKTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_LACellIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_ConcortisBiosystemsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_ScintillaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_SorrentoBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=srne_DirectorsAndNonEmployeeConsultantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=srne_DirectorsAndConsultantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=srne_ArkAnimalHealthIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended
	Oct. 31, 2015	May. 31, 2015	May. 31, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Sep. 30, 2009
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized				750,000,000		750,000,000
Common stock reserved for issuance				2,987,858
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield				0.00%	0.00%
Expected life of options				6 years 1 month 6 days	6 years 1 month 6 days
2009 Non-Employee Director Grants [Member] \| Non Employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance							8,000
Outstanding options vesting anniversary period				1 year
Shares available for grant				0
Option outstanding				0
2009 Non-Employee Director Grants [Member] \| Non Employee Directors \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options exercisable period				10 years
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options exercisable period				10 years
Option outstanding				3,024,718		2,957,616
Common stock, shares authorized				3,760,000
Employee option grants vested				25.00%
Unrecognized compensation cost related to unvested stock option grants				$ 7,186,000
Period for recognized compensation cost				2 years 9 months 18 days
Options Granted, Options Outstanding				380,450
2009 Stock Incentive Plan [Member] \| Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period				3 years
Stock options vesting rights under 2009 stock incentive plan				Employee option grants will generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years.
2009 Stock Incentive Plan [Member] \| Employee and Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 1,038,000	$ 982,000
2009 Stock Incentive Plan [Member] \| Non-Employee consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 52,000	420,000
Subsidiary Equity Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,400,000
Stock options vesting rights under 2009 stock incentive plan				Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding	0
Stock options, contractual term	10 years
Subsidiary Equity Grants [Member] \| Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Subsidiary Equity Grants [Member] \| TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				3,000,000
Stock options vesting rights under 2009 stock incentive plan				Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding		402,000
Options, weighted average grant date fair value				$ 0.84
Stock options, contractual term				10 years
Warrant shares exercisable		4,000,000
Warrant exercise price per share		$ 0.01
Warrants outstanding				9,500,000
Subsidiary Equity Grants [Member] \| TNK Therapeutics Inc [Member] \| Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance		10,000,000
Subsidiary Equity Grants [Member] \| LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				2,100,000
Stock options vesting rights under 2009 stock incentive plan				Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding		401,500
Options, weighted average grant date fair value				$ 0.20
Stock options, contractual term		10 years
Warrant shares exercisable		4,000,000
Warrant exercise price per share		$ 0.01
Warrants outstanding				9,500,000
Subsidiary Equity Grants [Member] \| LA Cell Inc [Member] \| Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance		10,000,000
Subsidiary Equity Grants [Member] \| Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,800,000
Stock options vesting rights under 2009 stock incentive plan				Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options Granted, Options Outstanding	9,750
Options, weighted average grant date fair value	$ 0.17
Stock options, contractual term	10 years
Warrant shares exercisable	4,000,000
Warrant exercise price per share	$ 0.25
Warrants outstanding				9,500,000
Subsidiary Equity Grants [Member] \| Concortis Biosystems, Corp. [Member] \| Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Subsidiary Equity Grants [Member] \| Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option outstanding				1,000,000
Stock options vesting rights under 2009 stock incentive plan				Stock options granted under this plan typically vest a portion immediately upon grant and the remaining options over two to four years or monthly over four years from the grant date and have a contractual term of ten years.
Options, weighted average grant date fair value				$ 0.01
Stock options, contractual term	10 years
Warrant shares exercisable	4,000,000
Warrant exercise price per share	$ 0.01
Warrants outstanding				9,500,000
Subsidiary Equity Grants [Member] \| Scintilla Pharmaceuticals, Inc [Member] \| Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	10,000,000
Options Granted, Options Outstanding	2,000
Subsidiary Equity Grants [Member] \| Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant shares exercisable	4,000,000
Warrant exercise price per share				$ 0.01
Warrants outstanding				9,500,000
Subsidiary Equity Grants [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	4 years
Subsidiary Equity Grants [Member] \| Maximum [Member] \| TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period				4 years
Warrant exercisable period		4 years
Subsidiary Equity Grants [Member] \| Maximum [Member] \| LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period		4 years
Warrant exercisable period		4 years
Subsidiary Equity Grants [Member] \| Maximum [Member] \| Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	4 years
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] \| Maximum [Member] \| Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	4 years
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] \| Maximum [Member] \| Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant exercisable period	4 years
Subsidiary Equity Grants [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	2 years
Subsidiary Equity Grants [Member] \| Minimum [Member] \| TNK Therapeutics Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period				2 years
Warrant exercisable period		40 months
Subsidiary Equity Grants [Member] \| Minimum [Member] \| LA Cell Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period		2 years
Warrant exercisable period		40 months
Subsidiary Equity Grants [Member] \| Minimum [Member] \| Concortis Biosystems, Corp. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	2 years
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] \| Minimum [Member] \| Scintilla Pharmaceuticals, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period	2 years
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] \| Minimum [Member] \| Sorrento Biologics Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant exercisable period	40 months
Subsidiary Equity Grants [Member] \| Non-Employee consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 48,000	0
Subsidiary Equity Grants [Member] \| CEO [Member] \| TNK Therapeutics Inc [Member] \| Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock		9,500,000
Voting rights				10 to 1
Subsidiary Equity Grants [Member] \| CEO [Member] \| LA Cell Inc [Member] \| Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock		9,500,000
Voting rights				10 to 1
Subsidiary Equity Grants [Member] \| CEO [Member] \| Concortis Biosystems, Corp. [Member] \| Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights				10 to 1
Subsidiary Equity Grants [Member] \| CEO [Member] \| Scintilla Pharmaceuticals, Inc [Member] \| Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights				10 to 1
Subsidiary Equity Grants [Member] \| CEO [Member] \| Sorrento Biologics Inc \| Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant granted to purchase common stock	9,500,000
Voting rights				10 to 1
Subsidiary Equity Grants [Member] \| Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 42,000	0
Period for recognized compensation cost				3 years 3 months 18 days
Unrecognized compensation cost related to unvested stock option and warrant grants				$ 492,000
Subsidiary Equity Grants [Member] \| Directors and Non-Employee Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Method used to determine the fair value of stock option and warrant				Black-Scholes option and warrant pricing model
Dividend yield				0.00%
Risk-free interest rate, minimum				1.39%
Risk-free interest rate, maximum				1.89%
Expected volatility, minimum				76.00%
Expected volatility, maximum				77.00%
Subsidiary Equity Grants [Member] \| Directors and Non-Employee Consultants [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options				6 years 1 month 6 days
Subsidiary Equity Grants [Member] \| Directors and Non-Employee Consultants [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options				4 years
Subsidiary Equity Grants [Member] \| Directors and Consultants [Member] \| Ark Animal Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding options vesting anniversary period			1 year
Option outstanding				351,000
Stock-based compensation				$ 0	$ 34,000
Unrecognized compensation cost related to unvested stock option grants				$ 0
Options Granted, Options Outstanding			600,000
Stock options, contractual term			10 years